Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. International, regional, and nationwide burden of Alzheimer ’ s illness and different dementias, 1990–2016: a scientific evaluation for the International Burden of Illness Examine 2016. Lancet Neurol. 2019;18:88–106.
Alzheimer’s Affiliation. Alzheimer’s illness details and figures. Alzheimers Dement. 2021;17(3):1–103.
Jack CR Jr, Bennett DA, Blennow Ok, Carrillo MC, Dunn B, Haeberlein S, Holtzman DM, et al. Towards a organic definition of Alzheimer’s illness. Alzheimers Dement. 2018;14(4):535–62.
Cummings J, Isaacson R, Schmitt F, Velting D. A sensible algorithm for managing Alzheimer’ s illness: what, when, and why ? Ann Clin Transl Neurol. 2015;2(3):307–23.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Towards defining the preclinical levels of Alzheimer’s illness: suggestions from the Nationwide Institute on Growing old-Alzheimer’s Affiliation workgroups on diagnostic pointers for Alzheimer’s illness. Alzheimers Dement. 2011;7(3):280–92.
Joling KJ, Janssen O, Francke AL, Verheij RA, Lissenberg-Witte BI, Pieter-Jelle V, et al. Time from analysis to institutionalization and demise in individuals with dementia. Alzheimers Dement. 2020;16(4):662–71.
Alzheimer’s Affiliation. Greater than regular ageing: understanding delicate cognitive impairment. 2022. https://www.alz.org/media/Paperwork/alzheimers-facts-and-figures-special-report.pdf
Zetterberg H. Blood-based biomarkers for Alzheimer’ s illness — An replace. J Neurosci Strategies. 2019;319:2–6.
Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer’s illness: in direction of scientific implementation. Lancet Neurol. 2021;S1474–4422(21):00361–6.
Schöll M, Maass A, Mattsson N, Ashton NJ, Blennow Ok, Zetterberg H, et al. Biomarkers for tau pathology. Mol Cell Neurosci. 2019;97:18–33.
de Toro J, Herschlik L, Mongini C, Waldner C. Rising roles of exosomes in regular and pathological situations: new insights for analysis and therapeutic functions. Entrance Immunol. 2015;6:203.
Kalluri R, LeBleu VS. The biology, perform, and biomedical functions of exosomes. Science. 2020;367:eaau6977.
Cano A, Ettcheto M, Bernuz M, Puerta R, Esteban de Antonio E, Souto EB, et al. Extracellular vesicles, the rising mirrors of mind physiopathology. Int J Biol Sci. 2023;19(3):721–43.
Wooden MJ, O’Loughlin AJ, Lakhal S. Exosomes and the blood–mind barrier: implications for neurological ailments. Ther Deliv. 2011;2(9):1095–9.
Zhang T, Ma S, Lv J, Wang X. The rising position of exosomes in Alzheimer’ s illness. Ageing Res Rev. 2021;68: 101321.
Sardar M, Anna S, Schultz A, Civitelli L, Hildesjö C, Larsson M, et al. Alzheimer’ s illness pathology propagation by exosomes containing poisonous amyloid – beta oligomers. Acta Neuropathol. 2018;136(1):41–56.
Zheng T, Pu J, Chen Y, Mao Y, Guo Z, Pan H. Plasma exosomes unfold and cluster round β -amyloid plaques in an animal mannequin of Alzheimer’ s illness. Entrance Growing old Neurosci. 2017;9:12.
Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, et al. Identification of preclinical Alzheimer’s illness by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control research. Alzheimers Dement. 2015;11(6):600-607.e1.
Kapogiannis D, Boxer A, Schwartz JB, Abner EL, Biragyn A, Masharani U, et al. Dysfunctionally phosphorylated kind 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer’s illness. FASEB J. 2015;29(2):589–96.
Mullins RJ, Mustapic M, Goetzl EJ, Kapogiannis D. Exosomal biomarkers of mind insulin resistance related to regional atrophy in Alzheimer’s illness. Hum Mind Mapp. 2017;38(4):1933–40.
Goetzl EJ, Boxer A, Schwartz JB, Abner EL, Petersen RC, Miller BL, et al. Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer illness. Neurology. 2015;85(1):40–7.
Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV, Goetzl L, Abner EL, et al. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s illness. FASEB J. 2016;30(2):4141–8.
Winston CN, Goetzl EJ, Schwartz JB, Elahi FM, Rissman RA. Complement protein ranges in plasma astrocyte-derived exosomes are irregular in conversion from delicate cognitive impairment to Alzheimer’s illness dementia. Alzheimers Dement (Amst). 2019;11:61–6.
Esteban de Antonio E, Pérez-Cordón A, Gil S, Orellana A, Cano A, Alegret M, et al. BIOFACE: a potential research of danger components, cognition, and biomarkers in a cohort of people with early-onset delicate cognitive impairment. research rationale and analysis protocols. J Alzheimers Dis. 2021;83(3):1233–49.
Alegret M, Sotolongo Grau O, De AEE, Cordón AP, Orellana A, Espinosa A, et al. Automatized FACEmemory® scoring is said to Alzheimer’ s illness phenotype and biomarkers in early – onset delicate cognitive impairment : the BIOFACE cohort Open Entry. Alzheimer’s Res Ther. 2022;14(1):43.
Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical elements of cerebrospinal fluid biomarker testing for Alzheimer’s illness analysis: a consensus paper from the Alzheimer’s biomarkers Standardization Initiative. Alzheimers Dement. 2012;8:65–73.
Molinuevo JL, Blennow Ok, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, et al. The scientific use of cerebrospinal fluid biomarker testing for Alzheimer’s illness analysis: a consensus paper from the Alzheimer’s biomarkers standardization initiative. Alzheimers Dement. 2014;10(6):808–17.
Leitão MJ, Silva-Spínola A, Santana I, Olmedo V, Nadal A, Le BN, et al. Medical validation of the Lumipulse G cerebrospinal fluid assays for routine analysis of Alzheimer’s illness. Alzheimers Res Ther. 2019;11(9):91.
Zhang Y, Bi J, Huang J, Tang Y, Du S, Li P. Exosome: a assessment of its classification, isolation methods, storage, diagnostic and focused remedy functions. Int J Nanomed. 2020;15:6917–34.
Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S, et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’ s illness. Acta Neuropathol Commun. 2019;7(1):169.
Assarsson E, Lundberg M, Holmquist G, Björkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting excessive sensitivity, specificity, and wonderful scalability. PLoS ONE. 2014;9(4): e95192.
Olink©Proteomics. Olink Goal 96 Neurology. 2021. https://olink.com/products-services/goal/neurology-panel/
Olink©Proteomics. Olink Goal 96 Irritation. 2021. https://olink.com/products-services/goal/irritation/
Orellana A, Garc P, Valero S, Montrreal L, De RI, Hern I, et al. Establishing In-Home Cutoffs of CSF Alzheimer’ s Illness Biomarkers for the AT (N) stratification of the Alzheimer Heart Barcelona Cohort. Int J Mol Sci. 2022;23:6891.
Sörensen A, Blazhenets G, Schiller F, Meyer PT, Frings L. Amyloid biomarkers as predictors of conversion from delicate cognitive impairment to Alzheimer’s dementia: a comparability of strategies. Alzheimers Res Ther. 2020;12(1):155.
Apostolova LG, Inexperienced AE, Babakchanian S, Hwang KS, Chou Y-Y, Toga AW, et al. Hippocampal atrophy and ventricular enlargement in regular ageing, delicate cognitive impairment (MCI), and Alzheimer Illness. Alzheimer Dis Assoc Disord. 2012;26(1):17–27.
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer’s illness: definition, pure historical past, and diagnostic standards. Alzheimers Dement. 2016;12(3):292–323.
DeTure MA, Dickson DW. The neuropathological analysis of Alzheimer’s illness. Mol Neurodegener. 2019;14(1):32.
Hampel H, Hardy J, Blennow Ok, Chen C, Perry G, Kim SH, et al. The amyloid-β pathway in Alzheimer’s illness. Mol Psychiatry. 2021;26(10):5481–503.
Frontera JA, Boutajangout A, Masurkar AV, Betensky RA, Ge Y, Vedvyas A, et al. Comparability of serum neurodegenerative biomarkers amongst hospitalized COVID-19 sufferers versus non-COVID topics with regular cognition, delicate cognitive impairment, or Alzheimer’s dementia. Alzheimers Dement. 2022;18(5):899–910.
Pase MP, Himali JJ, Aparicio HJ, Romero JR, Satizabal CL, Maillard P, et al. Plasma total-tau as a biomarker of stroke danger in the neighborhood. Ann Neurol. 2019;86(3):463–7.
Aparicio H, Himali J, Himali D, Romero J, Lioutas V-A, Pase M, et al. Affiliation of plasma nfl ranges with danger of heart problems within the framingham coronary heart research (S33.005). Neurology. 2022;98((18 Suppl)):1718.
Mustapic M, Eitan E, Werner JK Jr, Berkowitz ST, Lazaropoulos MP, Tran J, et al. Plasma extracellular vesicles enriched for neuronal origin: a possible window into mind pathologic processes. Entrance Neurosci. 2017;11:278.
Garcia Cumba LM, Peterson TE, Cepeda MA, Johnson AJ, Parney IF. Isolation and evaluation of plasma-derived exosomes in sufferers with glioma. Entrance Oncol. 2019;9:651.
Kumar A, Kim S, Su Y, Sharma M, Kumar P, Singh S, et al. Mind cell-derived exosomes in plasma function neurodegeneration biomarkers in male cynomolgus monkeys self-administrating oxycodone. EBioMedicine. 2021;63: 103192.
Sharma P, Diergaarde B, Ferrone S, Kirkwood JM, Whiteside TL. Melanoma cell-derived exosomes in plasma of melanoma sufferers suppress features of immune effector cells. Sci Rep. 2020;10:92.
Muller L, Hong C-S, Stolz DB, Watkins SC, Whiteside TL. Isolation of biologically-active exosomes from human plasma. J Immunol Strategies. 2014;411:55–65.
Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren Ok, et al. Conversion of amyloid constructive and unfavorable MCI to AD over 3 years An 11C-PIB PET research. Neurology. 2009;73(10):754–60.
Goetzl EJ, Schwartz JB, Abner EL, Jicha GA, Kapogiannis D. Excessive complement ranges in astrocyte-derived exosomes of Alzheimer illness. Ann Neurol. 2018;83(3):544–52.
Goetzl EJ, Abner EL, Jicha GA, Kapogiannis D, Schwartz JB. Declining ranges of functionally specialised synaptic proteins in plasma neuronal exosomes with development of Alzheimer’ s illness. FASEB J. 2018;32(2):888–93.
Ruan Z, Pathak D, Kalavai SV, Yoshii-kitahara A, Bhatt N, Takamatsu-yukawa Ok, et al. Alzheimer’ s illness brain-derived extracellular vesicles unfold tau pathology in interneurons. Mind. 2021;144:288–309.
Brinkmalm G, Zetterberg H. The phosphorylation cascade speculation of Alzheimer’s illness. Nature Growing old. 2021;1:498–9.
Forlenza OV, Miranda AS, Guimar I, Talib LL, Diniz BS, Gattaz WF, et al. Decreased neurotrophic assist is related to cognitive decline in non-demented topics. J Alzheimers Dis. 2015;46(2):423–9.
Straten G, Saur R, Laske C, Gasser T, Annas P, Basun H, et al. Affect of lithium remedy on GDNF serum and CSF concentrations in sufferers with early Alzheimer’s illness. Curr Alzheimer Res. 2011;8(8):853–9.
Morshed N, Lee MJ, Rodriguez FH, Lauffenburger DA, Mastroeni D, White FM. Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer’s illness. Nature Growing old. 2021;1:550–65.
Jonesco DS, Karsdal MA, Henriksen Ok. The CNS-specific proteoglycan, brevican, and its ADAMTS4-cleaved fragment present differential serological ranges in Alzheimer’s illness, different forms of dementia and non-demented controls: a cross-sectional research. PLoS ONE. 2020;15(6): e0234632.
Minta Ok, Brinkmalm G, Portelius E, Johansson P, Svensson J, Kettunen P, et al. Brevican and neurocan peptides as potential cerebrospinal fluid biomarkers for differentiation between vascular dementia and Alzheimer’s illness. J Alzheimers Dis. 2021;79(2):729–41.
Tedeschi Dauar M, Picard C, Rosa-Neto P, Villeneuve S, Poirier J. CNTN5 is related to illness danger and pathology all through the Alzheimer’s illness continuum. Alzheimers Dement. 2021;17(S3): e052359.
Mortamais M, Artero S, Ritchie Ok. White matter hyperintensities as early and unbiased predictors of Alzheimer’s illness danger. J Alzheimers Dis. 2014;42:393–400.
Moreno-Grau S, de Rojas I, Hernández I, Quintela I, Montrreal L, Alegret M, et al. Genome-wide affiliation evaluation of dementia and its scientific endophenotypes reveal novel loci related to Alzheimer’s illness and three causality networks: the GR@ACE mission. Alzheimers Dement. 2019;15(10):1333–47.
Nielsen JE, Pedersen KS, Vestergård Ok, Maltesen RG, Christiansen G, Lundbye-christensen S. Novel blood-derived extracellular vesicle-based proximity extension assay. Biomedicines. 2020;8:199.
Vom Berg J, Prokop S, Miller KR, Obst J, Kälin RE, Lopategui-Cabezas I, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat Med. 2012;18(12):1812–9.
Pedrini S, Gupta VB, Hone E, Doecke J, O’Bryant S, James I, et al. A blood-based biomarker panel signifies IL-10 and IL-12/23p40 are collectively related as predictors of β-amyloid load in an AD cohort. Sci Rep. 2017;7:14057.
Johansson P, Almqvist EG, Wallin A, Johansson J-O, Andreasson U, Blennow Ok, et al. Diminished cerebrospinal fluid focus of interleukin-12/23 subunit p40 in sufferers with cognitive impairment. PLoS ONE. 2017;12(5): e0176760.
Lin E, Kuo P-H, Liu Y-L, Yang AC, Tsai S-J. Affiliation and interplay results of interleukin-12 associated genes and bodily exercise on cognitive ageing in outdated adults within the Taiwanese inhabitants. Entrance Neurol. 2019;10:1065.
Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, et al. Ventricular enlargement as a potential measure of Alzheimer’s illness development validated utilizing the Alzheimer’s illness neuroimaging initiative database. Mind. 2008;131(9):2443–54.
Ertekin T, Acer N, Köseoğlu E, Zararsız G, Sönmez A, Gümüş Ok, et al. Whole intracranial and lateral ventricle volumes measurement in Alzheimer’s illness: a methodological research. J Clin Neurosci. 2016;34:133–9.
Walker KA, Hoogeveen RC, Folsom AR, Ballantyne CM, Knopman DS, Windham BG, et al. Midlife systemic inflammatory markers are related to late-life mind quantity. Neurology. 2017;89(22):2262–70.
Arevalo-Rodriguez I, Smailagic N, RoquéiFiguls M, Ciapponi A, Sanchez-Perez E, Giannakou A, et al. Mini-Psychological State Examination (MMSE) for the detection of Alzheimer’s illness and different dementias in individuals with delicate cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;2015(3):10783.
